Cargando…

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside

Bempedoic acid is a first-in-class, oral, inhibitor of cholesterol biosynthesis that is approved for use in patients with atherosclerotic cardiovascular disease (ASCVD) and for primary prevention in individuals with heterozygous familial hypercholesterolemia (HeFH) by the United States Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agarwala, Anandita, Quispe, Renato, Goldberg, Anne C, Michos, Erin D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121276/ https://www.ncbi.nlm.nih.gov/pubmed/34007155 http://dx.doi.org/10.2147/DDDT.S251865

Ejemplares similares

Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia
por: Govindaraju, Asvitha, et al.
Publicado: (2021)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
por: Laufs, Ulrich, et al.
Publicado: (2019)

New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia
por: Pirillo, Angela, et al.
Publicado: (2022)

Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

The effectiveness and value of bempedoic acid and inclisiran for heterozygous familial hypercholesterolemia and secondary prevention of ASCVD: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council
por: Agboola, Foluso, et al.
Publicado: (2021)

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis
por: Cicero, Arrigo F. G., et al.
Publicado: (2020)

Correction to: Role of Bempedoic Acid in Clinical Practice
por: Ballantyne, Christie M., et al.
Publicado: (2021)

Mipomersen in Familial Hypercholesterolemia: An Update on Health-Related Quality of Life and Patient-Reported Outcomes
por: Chambergo-Michilot, Diego, et al.
Publicado: (2022)

Diagnosis and Treatment of Heterozygous Familial Hypercholesterolemia
por: McGowan, Mary P., et al.
Publicado: (2019)

Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench
por: Pelliccia, Francesco, et al.
Publicado: (2022)

Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy
por: Ballantyne, Christie M, et al.
Publicado: (2019)

Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia: Systematic Review and Meta‐Analysis of Randomized Controlled Trials
por: Di Minno, Alessandro, et al.
Publicado: (2020)

Bempedoic acid for the treatment of dyslipidemia
por: Marrs, Joel C, et al.
Publicado: (2020)

Bempedoic Acid: for Whom and When
por: Ruscica, Massimiliano, et al.
Publicado: (2022)

Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
por: Thakkar, Aarti, et al.
Publicado: (2021)

Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
por: Banach, Maciej, et al.
Publicado: (2020)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Severe Hypertriglyceridemia After Use of Bempedoic Acid
por: Bovy, Valentin, et al.
Publicado: (2023)

From bench to bedside
por: Verdant, Colin L
Publicado: (2012)

Racial Disparities in Modifiable Risk Factors and Statin Usage in Black Patients With Familial Hypercholesterolemia
por: Agarwala, Anandita, et al.
Publicado: (2021)

Carotid and Aortic Stiffness in Patients with Heterozygous Familial Hypercholesterolemia
por: Ershova, Alexandra I., et al.
Publicado: (2016)

Bempedoic acid: what prospective uses?
por: Jacomelli, Ilaria, et al.
Publicado: (2023)

The IL-17 family in diseases: from bench to bedside
por: Huangfu, Longjie, et al.
Publicado: (2023)

Bench and Bedside
por: Schmidt, Christian
Publicado: (2002)

Lung Mechanics Over the Century: From Bench to Bedside and Back to Bench
por: Biselli, Paolo Jose Cesare, et al.
Publicado: (2022)

Sepsis: From Bench to Bedside
por: Silva, Eliézer, et al.
Publicado: (2008)

Sonochemotherapy: from bench to bedside
por: Lammertink, Bart H. A., et al.
Publicado: (2015)

Nutrition: From Bench to Bedside
por: Khan, Naim A., et al.
Publicado: (2016)

Linagliptin: from bench to bedside
por: Doupis, John
Publicado: (2014)

Pruritus: From the Bench to the Bedside
por: Reich, Adam, et al.
Publicado: (2018)

Olutasidenib: from bench to bedside
por: Venugopal, Sangeetha, et al.
Publicado: (2023)

Pharmacokinetics of bempedoic acid in patients with renal impairment
por: Amore, Benny M., et al.
Publicado: (2021)

An Update on New Cholesterol Inhibitor: Bempedoic Acid
por: Kulshreshtha, Mayank
Publicado: (2022)

Role of colesevelam in managing heterozygous familial hypercholesterolemia in adolescents and children
por: Sonnett, Travis, et al.
Publicado: (2010)

Awareness and knowledge of heterozygous familial hypercholesterolemia among Serbian pediatricians
por: Bjelakovic, Ljiljana, et al.
Publicado: (2023)

Drug addiction: from bench to bedside
por: Cheron, Julian, et al.
Publicado: (2021)

Nutrition in cachexia: from bench to bedside
por: Konishi, Masaaki, et al.
Publicado: (2016)

Cascade Screening and Treatment Initiation in Young Adults with Heterozygous Familial Hypercholesterolemia
por: Peterson, Amy L., et al.
Publicado: (2021)

Eosinophils and Lung Cancer: From Bench to Bedside
por: Sibille, Anne, et al.
Publicado: (2022)

Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
por: Ginsberg, Henry N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_63nr7m3qhlpio3ph2604c3h6l8